文献速递淋巴瘤

奥妥珠单抗联合苯达莫司汀治疗初治慢性淋巴细胞白血病患者:GREEN研究亚组分析

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.
PubMed 文献 · Leukemia · 2018-04-27

GREEN研究(NCT01905943)是一项非随机、开放标签IIIb期研究,评估奥妥珠单抗联合苯达莫司汀(G-B)治疗158例初治慢性淋巴细胞白血病(CLL)患者。主要终点为安全性/耐受性,3级及以上不良事件发生率为82.3%,总缓解率为81.0%,中位观察32.8个月时2年无进展生存率为81.8%。

要点

  • 3级及以上不良事件发生率为82.3%,最常见为中性粒细胞减少(49.4%)。
  • 总缓解率为81.0%,2年无进展生存率为81.8%。
  • 需仔细进行肿瘤溶解综合征风险评估、预处理和监测。

核心结论

  • 一线G-B方案在CLL中显示出可控的毒性和临床活性,需要仔细的肿瘤溶解综合征风险评估、预处理和监测。

研究设计与样本

  • GREEN(NCT01905943)是一项非随机、开放标签IIIb期研究,评估奥妥珠单抗单药或联合化疗治疗慢性淋巴细胞白血病(CLL)。
  • 本报告为预先计划的亚组分析,纳入158例接受奥妥珠单抗联合苯达莫司汀(G-B)治疗的初治CLL患者。
  • 患者接受6个28天周期(C)的G-B方案:奥妥珠单抗第1周期第1天25 mg、第2天975 mg,第1周期第8天和第15天1000 mg,第2-6周期第1天1000 mg;苯达莫司汀第1-6周期第1天和第2天70/90 mg/m²。

主要发现

  • 3级及以上不良事件发生率为82.3%,包括中性粒细胞减少(49.4%)、血小板减少(12.0%)和发热性中性粒细胞减少(10.8%)。
  • 严重不良事件包括中性粒细胞减少(12.7%)、发热性中性粒细胞减少(9.5%)和肺炎(7.6%)。
  • 3级及以上感染和输注相关反应的发生率分别为20.3%和17.1%。
  • 因肿瘤溶解综合征(TLS;8.2%),包括两例相关死亡(其中一例发生在另一研究队列),实施了额外的风险最小化措施。
  • 总缓解率为81.0%;中位观察时间为32.8个月,2年无进展生存率为81.8%。

临床怎么用

  • 作者认为一线G-B方案在CLL中显示出可控的毒性和临床活性。
  • 作者指出需要仔细的肿瘤溶解综合征风险评估、预处理和监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab-bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2-6; and bendamustine 70/90 mg/m2 D1 and D2 of C1-6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neutropenia (12.7%), febrile neutropenia (9.5%) and pneumonia (7.6%). Rates of grade ≥3 infections and infusion-related reactions were 20.3% and 17.1%, respectively. Due to tumor lysis syndrome (TLS; 8.2%), including two associated fatalities (one in another study cohort), additional risk-minimization measures were implemented. Overall response rate was 81.0%. After 32.8 months' median observation time, 2-year progression-free survival was 81.8%. Minimal residual disease was undetectable in 59.5% (94/158) and 27.8% (44/158) of patients for blood and bone marrow, respectively. Frontline G-B appears to have manageable toxicity with clinical activity in CLL. Careful TLS risk assessment, pretreatment and monitoring is required.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Stilgenbauer S, Leblond V, Foà R, et al. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018. PMID: 29749403. doi:10.1038/s41375-018-0146-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。